NCT01458847 - Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

DRUG

cis-UCA solution

Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients

DRUG

cis-UCA solution

Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients

DRUG

cis-UCA solution

Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients

Trial Locations (2)

Turku University Hospital, Department of Surgery, Division of Urology, Turku

Tampere University Hospital, Department of Urology, Tampere